endocrinology
AUSDRISK — Australian Type 2 Diabetes Risk Tool
10-item validated risk assessment tool for identifying Australians at high risk of developing type 2 diabetes within 5 years. Also used internationally. Score ≥12 = high risk. Equivalent to FINDRISC adapted for Australian population.
References
- Chen L et al. AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures. Med J Aust. 2010;192(4):197–202.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Tirzepatide · Dual GIP/GLP-1 Receptor Agonist — Type 2 Diabetes / Obesity
- Thiamine (IV/IM — Pabrinex) · Vitamin B1 (Thiamine) — deficiency treatment / Wernicke's encephalopathy prevention
- Botulinum Toxin Type A (ENT) · Neuromuscular Blocking Agent (Botulinum Toxin)
- Anthrax Vaccine · Vaccine (Bacterial — Anthrax Prevention)
- Edoxaban (AF Stroke Prevention / VTE) · Direct Factor Xa Inhibitor (DOAC)
- Valganciclovir · Prodrug Antiviral — CMV Prevention and Treatment (Oral)
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
- Pituitary Apoplexy · ENEA 2011 / Pituitary Society
- Hypercalcaemia Management · NICE / Endocrine Society
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.